This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DeFeo-Jones, D. Articles by Jones, R. E. Search for Related Content PubMed PubMed Citation Articles by DeFeo-Jones, D. Articles by Jones, R. E.

¹ Department of Cancer Research and ² Technology Enabled Synthesis Group, Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania

Requests for reprints: Raymond E Jones, Department of Cancer Research, Merck Research Laboratories, Building 26-462, West Point, PA 19486. Phone: 215-652-7637; Fax: 215-993-3398. E-mail: raymond_jones{at}merck.com

Recent studies indicate that dysregulation of the Akt/PKB family of serine/threonine kinases is a prominent feature of many human cancers. The Akt/PKB family is composed of three members termed Akt1/PKB, Akt2/PKBß, and Akt3/PKB. It is currently not known to what extent there is functional overlap between these family members. We have recently identified small molecule inhibitors of Akt. These compounds have pleckstrin homology domain-dependent, isozyme-specific activity. In this report, we present data showing the relative contribution that inhibition of the different isozymes has on the apoptotic response of tumor cells to a variety of chemotherapies. In multiple cell backgrounds, maximal induction of caspase-3 activity is achieved when both Akt1 and Akt2 are inhibited. This induction is not reversed by overexpression of functionally active Akt3. The level of caspase-3 activation achieved under these conditions is equivalent to that observed with the phosphatidylinositol-3-kinase inhibitor LY294002. We also show that in different tumor cell backgrounds inhibition of mammalian target of rapamycin, a downstream substrate of Akt, is less effective in inducing caspase-3 activity than inhibition of Akt1 and Akt2. This shows that the survival phenotype conferred by Akt can be mediated by signaling pathways independent of mammalian target of rapamycin in some tumor cell backgrounds. Finally, we show that inhibition of both Akt1 and Akt2 selectively sensitizes tumor cells, but not normal cells, to apoptotic stimuli.

Key Words: Selective inhibition • apoptosis • Akt

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 9/ 7/04; revised 11/10/04; accepted 11/22/04.

This article has been cited by other articles:

				Y. Zhan, N. Ginanni, M. R. Tota, M. Wu, N. W. Bays, V. M. Richon, N. E. Kohl, E. S. Bachman, P. R. Strack, and S. Krauss Control of Cell Growth and Survival by Enzymes of the Fatty Acid Synthesis Pathway in HCT-116 Colon Cancer Cells Clin. Cancer Res., September 15, 2008; 14(18): 5735 - 5742. [Abstract] [Full Text] [PDF]

				S. A. Siddiqi and C. M. Mansbach II PKC{zeta}-mediated phosphorylation controls budding of the pre-chylomicron transport vesicle J. Cell Sci., July 15, 2008; 121(14): 2327 - 2338. [Abstract] [Full Text] [PDF]

				M. Cheung, A. Sharma, S. V. Madhunapantula, and G. P. Robertson Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development Cancer Res., May 1, 2008; 68(9): 3429 - 3439. [Abstract] [Full Text] [PDF]

				N. Rhodes, D. A. Heerding, D. R. Duckett, D. J. Eberwein, V. B. Knick, T. J. Lansing, R. T. McConnell, T. M. Gilmer, S.-Y. Zhang, K. Robell, et al. Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity Cancer Res., April 1, 2008; 68(7): 2366 - 2374. [Abstract] [Full Text] [PDF]

				D. Xiao and S. V. Singh z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo Mol. Cancer Ther., January 1, 2008; 7(1): 171 - 180. [Abstract] [Full Text] [PDF]

				Z. Cao, L. Liu, W. Packwood, M. Merkel, P. D. Hurn, and D. M. Van Winkle Sex differences in the mechanism of Met5-enkephalin-induced cardioprotection: role of PI3K/Akt Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H302 - H310. [Abstract] [Full Text] [PDF]

				L. Logie, A. J. Ruiz-Alcaraz, M. Keane, Y. L. Woods, J. Bain, R. Marquez, D. R. Alessi, and C. Sutherland Characterization of a Protein Kinase B Inhibitor In Vitro and in Insulin-Treated Liver Cells Diabetes, September 1, 2007; 56(9): 2218 - 2227. [Abstract] [Full Text] [PDF]

				L. M. Ballou, E. S. Selinger, J. Y. Choi, D. G. Drueckhammer, and R. Z. Lin Inhibition of Mammalian Target of Rapamycin Signaling by 2-(Morpholin-1-yl)pyrimido[2,1-{alpha}]isoquinolin-4-one J. Biol. Chem., August 17, 2007; 282(33): 24463 - 24470. [Abstract] [Full Text] [PDF]

				S. V. Madhunapantula, A. Sharma, and G. P. Robertson PRAS40 Deregulates Apoptosis in Malignant Melanoma Cancer Res., April 15, 2007; 67(8): 3626 - 3636. [Abstract] [Full Text] [PDF]

				D. Xiao and S. V. Singh Phenethyl Isothiocyanate Inhibits Angiogenesis In vitro and Ex vivo Cancer Res., March 1, 2007; 67(5): 2239 - 2246. [Abstract] [Full Text] [PDF]

				L. Heron-Milhavet, C. Franckhauser, V. Rana, C. Berthenet, D. Fisher, B. A. Hemmings, A. Fernandez, and N. J. C. Lamb Only Akt1 Is Required for Proliferation, while Akt2 Promotes Cell Cycle Exit through p21 Binding Mol. Cell. Biol., November 15, 2006; 26(22): 8267 - 8280. [Abstract] [Full Text] [PDF]

				F. Acconcia, B. Manavathi, J. Mascarenhas, A. H. Talukder, G. Mills, and R. Kumar An Inherent Role of Integrin-Linked Kinase-Estrogen Receptor {alpha} Interaction in Cell Migration. Cancer Res., November 15, 2006; 66(22): 11030 - 11038. [Abstract] [Full Text] [PDF]

				E. Gonzalez and T. E. McGraw Insulin Signaling Diverges into Akt-dependent and -independent Signals to Regulate the Recruitment/Docking and the Fusion of GLUT4 Vesicles to the Plasma Membrane Mol. Biol. Cell, October 1, 2006; 17(10): 4484 - 4493. [Abstract] [Full Text] [PDF]

				M.-L. Chen, P.-Z. Xu, X. Peng, W. S. Chen, G. Guzman, X. Yang, A. Di Cristofano, P. P. Pandolfi, and N. Hay The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes & Dev., June 15, 2006; 20(12): 1569 - 1574. [Abstract] [Full Text] [PDF]

				D. Sampath, J. Cortes, Z. Estrov, M. Du, Z. Shi, M. Andreeff, V. Gandhi, and W. Plunkett Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial Blood, March 15, 2006; 107(6): 2517 - 2524. [Abstract] [Full Text] [PDF]

				P. Narayan, B. Holt, R. Tosti, and L. P. Kane CARMA1 Is Required for Akt-Mediated NF-{kappa}B Activation in T Cells. Mol. Cell. Biol., March 1, 2006; 26(6): 2327 - 2336. [Abstract] [Full Text] [PDF]

				C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689. [Abstract] [Full Text] [PDF]